Global Metabolism Drugs Market: Restraint
The major factors that hinder the growth of the global metabolism drugs market include clinical hold on trials by market players. For instance, on June 26, 2022, Astellas Pharma Inc., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the FORTIS Phase 1/2 trial following the occurrence of a serious adverse event (SAE) of peripheral sensory neuropathy in one of the trial participants. FORTIS is a clinical trial evaluating AT845, an investigational adeno-associated virus (AAV) gene replacement therapy in adults with Late-Onset Pompe Disease.
Global Metabolism Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency on January 30, 2020.
The COVID-19 can affect the economy in three main ways by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with regard to the transportation of drugs from one place to another place which affected the research and development activities for metabolism drugs development.
Metabolism Drugs Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients